Novartis-Dr Reddy’s Sales Pact, Job Cuts: Are Foreign Firms Altering India Push?
Novartis India To Let Go Of About 400 Employees
Executive Summary
Novartis India hands over sales and distribution of certain established brands, accounting for 50% of the 2020-2021 product revenues, to Dr Reddy’s as more foreign firms opt to leverage ground strengths of local players. Does it represent a wider trend where foreign firms are re-calibrating operations in India to focus energies on specialty and patented products?
You may also be interested in...
Eisai Shrinks India Multiple Sclerosis Commercial Team
Eisai recalibrates sales and marketing efforts for Biogen’s multiple sclerosis portfolio in India, joining a growing list of foreign firms that appear to be rightsizing their commercial engine in an ultra-competitive market.
'Brands Don’t Die': Cipla Grabs Rights To Novartis’ Galvus In India
Novartis draws up perpetual license agreement with Cipla for its vildagliptin brand in India. Experts weigh in on some deal nuances and whether the DPP-4 inhibitor can deliver long-term value in an ultra-competitive segment.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.